Clinical Trials for Non-Small Cell Lung Cancer

A Phase Ib/II, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Glumetinib (SCC244), a Selective MET Inhibitor in Patients With Advanced Non-Small Cell Lung Cancer Harboring MET-alterations

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with unresectable stage IIIB/IIIC or stage IV NSCLC harboring MET alterations receive oral glumetinib (gumarontinib), a selective MET receptor tyrosine kinase inhibitor. The global cohort focuses on MET exon 14 skipping–positive disease in patients who cannot receive or decline chemotherapy, or who have progressed after one or two systemic regimens; prior MET inhibitor treatment is not allowed.

ClinicalTrials.gov ID: NCT04270591

A Phase I/II Study of Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab in Advanced Solid Tumors (PNeoVCA)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial involves adults with unresectable or metastatic advanced solid tumors who have progressed on prior treatments or are candidates for pembrolizumab, combining pembrolizumab, which targets the PD-1 receptor to enhance immune response, with a personalized neoantigen peptide vaccine designed to stimulate an individualized immune attack against tumor-associated proteins.

ClinicalTrials.gov ID: NCT05269381

A Randomized Phase II Study of INC280 (Capmatinib) Plus Osimertinib With or Without Ramucirumab in Participants With EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: The trial enrolls patients with advanced or recurrent non-small cell lung cancer having EGFR mutations and MET amplification, who progressed after osimertinib, to assess the efficacy of capmatinib (a MET inhibitor) and osimertinib with or without ramucirumab (an anti-angiogenic antibody).

ClinicalTrials.gov ID: NCT05642572

Phase I Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Dosimetry, and Preliminary Activity of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated, unresectable locally advanced or metastatic pancreatic, non-small cell lung, HR+/HER2− breast, or triple-negative breast cancer—and colorectal cancer during dose escalation only—undergo screening with the FAP-targeted PET tracer [68Ga]Ga-NNS309. Patients with tracer-avid tumors receive [177Lu]Lu-NNS309, a FAP-targeted radioligand that delivers beta radiation to tumor stroma and nearby cancer cells.

ClinicalTrials.gov ID: NCT06562192

A Phase 1b/2a Multi-Center, Dose Escalation and Reference Regimen-Controlled, Multi-Cohort Study to Determine the Safety and Efficacy of Oral 7HP349 (Alintegimod) in Combination with Ipilimumab Followed by Nivolumab Monotherapy in Patients with Locally Advanced or Metastatic Cancers Following One or More Prior Therapies

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with measurable, locally advanced or metastatic solid tumors after at least one prior therapy are eligible for the currently enrolling dose-escalation cohorts, including patients previously treated with anti–PD-1/PD-L1 therapy. Treatment is oral alintegimod, an investigational LFA-1/VLA-4 integrin agonist, initially alone and then with ipilimumab, followed by nivolumab monotherapy.

ClinicalTrials.gov ID: NCT06362369

A Phase 1, First-in-Human, Open-Label, Multi-Center, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LB-LR1109 for the Treatment of Advanced or Metastatic Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced or metastatic NSCLC, head and neck squamous cell carcinoma, renal cell carcinoma, urothelial carcinoma, or melanoma who lack a suitable standard treatment option receive escalating doses of LB-LR1109 monotherapy. This investigational antibody blocks the inhibitory immune receptor LILRB1 to enhance antitumor immune activity.

ClinicalTrials.gov ID: NCT06332755

PNV21-001: A Phase I Study of a Personalized Multi-Peptide Neo-Antigen Vaccine in Breast Cancer, PD1/PD-L1 Inhibitor-Refractory Melanoma, and Pretreated Non-Small Cell Lung Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial evaluates a personalized multi-peptide neo-antigen vaccine combined with poly ICLC and the PD-1 inhibitor nivolumab in adult patients with advanced, treatment-resistant stage IIIC-IV melanoma, hormone receptor positive HER2-negative metastatic breast cancer, and stage III-IV non-small cell lung cancer, focusing on safety and immune response.

ClinicalTrials.gov ID: NCT05098210

A Phase 1, Open-label, Dose Escalation and Dose Expansion Study for LNCB74, a B7-H4 Targeted Antibody Drug Conjugate, as Monotherapy in Participants With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable or metastatic solid tumors and ECOG performance status 0–1 receive LNCB74 monotherapy in dose-escalation and expansion cohorts. LNCB74 is an investigational B7-H4–targeted antibody–drug conjugate carrying the microtubule-disrupting payload MMAE.

ClinicalTrials.gov ID: NCT06774963

A Phase 1, Multicenter, Open-label, Dose-escalation Study Evaluating the Safety and Tolerability of Intravenous KK2269 Monotherapy and Combination Therapy With Docetaxel in Adult Participants With Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with measurable advanced or metastatic non-CNS solid tumors and ECOG 0–1 receive escalating intravenous doses of KK2269, an investigational EpCAM×CD40 bispecific antibody designed to activate CD40 near EpCAM-positive tumors. A combination cohort receives KK2269 plus docetaxel after prior systemic therapy for gastric, gastroesophageal junction, or esophageal adenocarcinoma or NSCLC; patients must be docetaxel-eligible and docetaxel-naive.

ClinicalTrials.gov ID: NCT06266299

A Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-53038, a Pan-KRAS Inhibitor, as Monotherapy or in Combinations in Patients With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplifications

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced or metastatic solid tumors harboring a KRAS mutation or high-level KRAS wild-type amplification receive the investigational oral pan-KRAS inhibitor BGB-53038 alone or with tislelizumab (anti–PD-1) for nonsquamous NSCLC or cetuximab (anti-EGFR) for colorectal cancer. The study has been terminated, in part because of a lack of promising efficacy.

ClinicalTrials.gov ID: NCT06585488